Welch & Forbes’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $110M | Buy |
221,304
+1,635
| +0.7% | +$725K | 1.34% | 22 |
|
|
2026
Q1 | $98.1M | Buy |
219,669
+1,471
| +0.7% | +$686K | 1.27% | 22 |
|
|
2025
Q4 | $98.9M | Sell |
218,198
-2,148
| -1% | -$926K | 1.2% | 23 |
|
|
2025
Q3 | $86.3M | Buy |
220,346
+3,102
| +1% | +$1.3M | 1.04% | 29 |
|
|
2025
Q2 | $96.7M | Buy |
217,244
+9,605
| +5% | +$4.43M | 1.21% | 23 |
|
|
2025
Q1 | $101M | Buy |
207,639
+9,858
| +5% | +$4.59M | 1.32% | 24 |
|
|
2024
Q4 | $79.6M | Buy |
197,781
+1,162
| +0.6% | +$539K | 1.02% | 30 |
|
|
2024
Q3 | $91.4M | Buy |
196,619
+1,722
| +0.9% | +$827K | 1.16% | 27 |
|
|
2024
Q2 | $94.3M | Buy |
194,897
+1,956
| +1% | +$849K | 1.26% | 23 |
|
|
2024
Q1 | $80.7M | Buy |
192,941
+4,554
| +2% | +$1.93M | 1.11% | 29 |
|
|
2023
Q4 | $76.7M | Buy |
188,387
+3,317
| +2% | +$1.23M | 1.16% | 27 |
|
|
2023
Q3 | $64.4M | Buy |
185,070
+266
| +0.1% | +$93K | 1.06% | 32 |
|
|
2023
Q2 | $65M | Sell |
184,804
-1,414
| -0.8% | -$476K | 1.03% | 32 |
|
|
2023
Q1 | $58.7M | Sell |
186,218
-1,953
| -1% | -$586K | 0.99% | 33 |
|
|
2022
Q4 | $54.3M | Sell |
188,171
-1,287
| -0.7% | -$392K | 0.97% | 34 |
|
|
2022
Q3 | $54.9M | Sell |
189,458
-2,775
| -1% | -$798K | 1.07% | 31 |
|
|
2022
Q2 | $54.2M | Sell |
192,233
-3,325
| -2% | -$890K | 0.99% | 30 |
|
|
2022
Q1 | $51M | Buy |
195,558
+5,628
| +3% | +$1.34M | 0.8% | 39 |
|
|
2021
Q4 | $41.7M | Sell |
189,930
-12,107
| -6% | -$2.35M | 0.62% | 45 |
|
|
2021
Q3 | $36.6M | Sell |
202,037
-4,332
| -2% | -$846K | 0.61% | 45 |
|
|
2021
Q2 | $41.6M | Sell |
206,369
-3,311
| -2% | -$693K | 0.7% | 40 |
|
|
2021
Q1 | $45.1M | Buy |
209,680
+18,312
| +10% | +$4.02M | 0.83% | 38 |
|
|
2020
Q4 | $45.2M | Buy |
191,368
+6,686
| +4% | +$1.53M | 0.88% | 34 |
|
|
2020
Q3 | $50.3M | Sell |
184,682
-1,816
| -1% | -$501K | 1.08% | 26 |
|
|
2020
Q2 | $54.1M | Buy |
186,498
+4,131
| +2% | +$1.12M | 1.27% | 25 |
|
|
2020
Q1 | $43.4M | Buy |
182,367
+7,499
| +4% | +$1.72M | 1.21% | 25 |
|
|
2019
Q4 | $38.3M | Sell |
174,868
-1,646
| -0.9% | -$333K | 0.85% | 37 |
|
|
2019
Q3 | $29.9M | Buy |
176,514
+587
| +0.3% | +$104K | 0.71% | 47 |
|
|
2019
Q2 | $32.3M | Buy |
175,927
+1,477
| +0.8% | +$258K | 0.79% | 42 |
|
|
2019
Q1 | $32.1M | Sell |
174,450
-1,600
| -0.9% | -$296K | 0.81% | 43 |
|
|
2018
Q4 | $29.2M | Sell |
176,050
-386
| -0.2% | -$66.9K | 0.82% | 40 |
|
|
2018
Q3 | $34M | Buy |
176,436
+3,845
| +2% | +$685K | 0.81% | 42 |
|
|
2018
Q2 | $29.3M | Sell |
172,591
-4,450
| -3% | -$690K | 0.76% | 44 |
|
|
2018
Q1 | $28.9M | Sell |
177,041
-1,212
| -0.7% | -$198K | 0.74% | 45 |
|
|
2017
Q4 | $26.7M | Sell |
178,253
-2,421
| -1% | -$358K | 0.71% | 47 |
|
|
2017
Q3 | $27.5M | Sell |
180,674
-5,751
| -3% | -$866K | 0.72% | 51 |
|
|
2017
Q2 | $24M | Buy |
186,425
+651
| +0.4% | +$78.4K | 0.67% | 52 |
|
|
2017
Q1 | $20.3M | Sell |
185,774
-4,119
| -2% | -$363K | 0.58% | 64 |
|
|
2016
Q4 | $14M | Sell |
189,893
-2,767
| -1% | -$225K | 0.42% | 79 |
|
|
2016
Q3 | $16.8M | Sell |
192,660
-5,242
| -3% | -$495K | 0.58% | 59 |
|
|
2016
Q2 | $17M | Buy |
197,902
+3,733
| +2% | +$323K | 0.52% | 67 |
|
|
2016
Q1 | $15.4M | Buy |
194,169
+564
| +0.3% | +$51K | 0.48% | 70 |
|
|
2015
Q4 | $24.4M | Buy |
193,605
+299
| +0.2% | +$36.1K | 0.78% | 44 |
|
|
2015
Q3 | $20.1M | Sell |
193,306
-805
| -0.4% | -$103K | 0.67% | 54 |
|
|
2015
Q2 | $24M | Sell |
194,111
-9,853
| -5% | -$1.24M | 0.75% | 45 |
|
|
2015
Q1 | $24.1M | Sell |
203,964
-2,814
| -1% | -$337K | 0.72% | 47 |
|
|
2014
Q4 | $24.6M | Sell |
206,778
-5,045
| -2% | -$568K | 0.72% | 43 |
|
|
2014
Q3 | $23.8M | Sell |
211,823
-731
| -0.3% | -$69.6K | 0.73% | 49 |
|
|
2014
Q2 | $20.1M | Sell |
212,554
-10,306
| -5% | -$723K | 0.64% | 58 |
|
|
2014
Q1 | $15.8M | Sell |
222,860
-2,032
| -0.9% | -$161K | 0.5% | 71 |
|
|
2013
Q4 | $16.7M | Sell |
224,892
-13,841
| -6% | -$964K | 0.53% | 69 |
|
|
2013
Q3 | $18.1M | Sell |
238,733
-11,865
| -5% | -$944K | 0.61% | 60 |
|
|
2013
Q2 | $20.1M | Buy |
+250,598
| New | +$18.5M | 0.72% | 55 |
|
Other funds holding VRTX
Welch & Forbes's VRTX Position: Q2 2026 in Review
Welch & Forbes increased its Vertex Pharmaceuticals (VRTX) stake by 0.74% in Q2 2026, buying an estimated $725K and bringing the position to 221,304 shares worth $110M. The position accounts for 1.34% of the portfolio, ranked #22.
Welch & Forbes first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Welch & Forbes held 221,304 shares of Vertex Pharmaceuticals worth $110M as of Q2 2026.
- Welch & Forbes bought 1,635 Vertex Pharmaceuticals shares in Q2 2026, an estimated $725K.
- Vertex Pharmaceuticals made up 1.34% of Welch & Forbes's portfolio in Q2 2026, its #22 holding.
- Welch & Forbes first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Welch & Forbes's 13F filing for Q2 2026, filed 30 Jul 2026.